Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):436-9. doi: 10.1097/MPG.0b013e318253cff1.
Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95-0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100 μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined.
粪便钙卫蛋白（一种黏膜炎症的替代标志物）的评估是监测小儿炎症性肠病治疗反应的一种很有前途的方法，尤其是如果结果能够快速获得。我们在 56 例克罗恩病患儿的 134 份粪便样本中测试了新型钙卫蛋白快速检测法（Quantum Blue）与传统酶联免疫吸附试验的性能。组内相关系数分析反映了良好的一致性（组内相关系数 0.97[95%置信区间 0.95-0.98]），但在不需要稀释的较低值时一致性更好。使用 100μg/g 作为正常值的截断值，两种检测方法的百分比一致性为 87%。指导炎症性肠病治疗的最佳临界值还有待确定。
